Skip to main content
eScholarship
Open Access Publications from the University of California

UCLA

UCLA Electronic Theses and Dissertations bannerUCLA

Disease Response in Rheumatoid Arthritis Across Four Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity

Abstract

Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme, which has been implicated as a biomarker of cardiovascular (CV) risk in patients with rheumatoid arthritis (RA).

Methods: 1213 adult RA patients in the CERTAIN registry with moderate or high disease activity (CDAI >10) who initiated a biologic agent that had not been previously used for their treatment (tocilizumab (TCZ), n=296; abatacept (ABA), n= 374; TNFα inhibitors (TNFi) n= 427; rituximab (RTX), n=116) had serum specimens analyzed for PON1 activity by arylesterase (ARYL), lactonase (LAC) and paraoxonase (PON) assays at baseline and after 6 months of new biologic therapy. A targeted panel of oxylipins was evaluated in a subset of patients with the lowest and highest 6-month DAS28 responses in each treatment group.

Results: PON1 activity increased in the entire cohort after 6 months of new biologic therapy, showing the greatest, most consistent increases in the TCZ group. Increases in the LAC and ARYL activities of PON1 after 6 months of therapy associated with treatment response to new biologic therapies measured by DAS28, CDAI, and ACR 20, 50, or 70 responses (OR (CI 95%) of 3.33 (1.52, 7.27), and 3.37 (1.45, 7.83), p<0.005 for ACR responses (LAC/ARYL) respectively), after controlling for other RA disease characteristics. DAS28-CRP high responders had significantly greater decreases in 12-HETE (p=0.0005) than low responders.

Conclusion: Improvement in disease activity across 4 classes of biologic therapies with different mechanisms of action associates with improvement in the activity of PON1, a protein associated with reduction in systemic oxidative stress and CV risk.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View